Frimodt-Moeller J, Poulsen D L, Kornerup H J, Bech P
Department of Medicine, Hilleroed Hospital, Denmark.
J Hum Hypertens. 1991 Jun;5(3):215-21.
In a double-blind, parallel-group multicentre study in general practice, lisinopril (10-20 mg once daily) was compared with metoprolol (100-200 mg once daily) in 360 patients whose diastolic blood pressure (DBP) was in the range 91-115 mmHg despite diuretic treatment. Following a three week run-in period during which the diuretic was withdrawn, monotherapy with either lisinopril or metoprolol was given for two months with dose doubled after one month if DBP remained greater than 90 mmHg. Quality of life was assessed using established and validated questionnaires at the time of cessation of diuretic treatment and again after two months's active treatment. Both metoprolol and lisinopril achieved statistically significant BP reduction relative to baseline (P less than 0.001). Significantly fewer adverse events were experienced on lisinopril and metoprolol than on diuretic treatment. Frequency of withdrawals due to adverse events were statistically significantly lower on lisinopril than metoprolol P = 0.01. Before treatment approximately 35% of the patients had quality of life problems measured by General Health Questionnaire (GHQ), which was reduced to 17% on lisinopril and 23% on metoprolol. Thus both metoprolol and lisinopril were effective and safe in the treatment of mild to moderate essential hypertension with lisinopril being better tolerated. From patients' self-assessments of quality of life, lisinopril was found to be superior to metoprolol in some aspects of emotional, cognitive and social functioning.
在一项全科医疗的双盲、平行组多中心研究中,将赖诺普利(每日一次,10 - 20毫克)与美托洛尔(每日一次,100 - 200毫克)进行比较,研究对象为360例尽管接受了利尿剂治疗但舒张压(DBP)仍在91 - 115毫米汞柱范围内的患者。在为期三周的导入期内停用利尿剂,之后给予赖诺普利或美托洛尔单药治疗两个月,若DBP仍高于90毫米汞柱,则在一个月后将剂量加倍。在停用利尿剂治疗时以及积极治疗两个月后,使用已确立并经验证的问卷对生活质量进行评估。与基线相比,美托洛尔和赖诺普利均实现了具有统计学意义的血压降低(P小于0.001)。与利尿剂治疗相比,赖诺普利和美托洛尔的不良事件明显更少。因不良事件导致的停药频率,赖诺普利在统计学上显著低于美托洛尔(P = 0.01)。治疗前,约35%的患者通过一般健康问卷(GHQ)测量存在生活质量问题,在赖诺普利治疗组该比例降至17%,在美托洛尔治疗组降至23%。因此,美托洛尔和赖诺普利在治疗轻至中度原发性高血压方面均有效且安全,赖诺普利的耐受性更好。从患者对生活质量的自我评估来看,发现赖诺普利在情绪、认知和社会功能的某些方面优于美托洛尔。